Longitudinal association of type 2 diabetes and insulin therapy with muscle parameters in the KORA-Age study
Autor: | Uta Ferrari, Canan Selte, Barbara Thorand, Michael Drey, Marietta Rottenkolber, Romy Conzade, Annette Peters, Birgit Linkohr, Cornelia Then, Jochen Seissler |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
medicine.medical_specialty Sarcopenia Endocrinology Diabetes and Metabolism medicine.medical_treatment Population 030209 endocrinology & metabolism Timed Up and Go test Type 2 diabetes 030204 cardiovascular system & hematology 03 medical and health sciences Grip strength 0302 clinical medicine Endocrinology Diabetes Insulin Kora-age Muscle Function Muscle Mass Risk Factors Internal medicine Diabetes mellitus Germany Internal Medicine medicine Humans Longitudinal Studies Muscle Strength education Muscle Skeletal Exercise Geriatric Assessment Postural Balance Aged Aged 80 and over education.field_of_study Hand Strength business.industry Skeletal muscle General Medicine medicine.disease medicine.anatomical_structure Diabetes Mellitus Type 2 Time and Motion Studies Female business Follow-Up Studies |
Zdroj: | Acta Diabetol. 57, 1057-1063 (2020) |
ISSN: | 1432-5233 |
Popis: | Aims: The aim of the current study was to investigate the association of type 2 diabetes (T2D) and insulin treatment with changes in muscle mass, muscle strength, and physical performance in older adults. Methods: In 731 participants of the population-based KORA-Age study aged 74.6 ± 6.2years (T2D: n = 118; insulin treatment: n = 20), skeletal muscle index (SMI [kg/m2]), hand grip strength (GS [kg]), and a timed up and go test (TUG [s]) were performed at baseline and after a follow-up time of 3years. The association of T2D and insulin therapy with changes in muscle parameters was analyzed using linear regression models. Results: After adjustment for sex, age, BMI, physical activity, smoking, and multimorbidity, T2D was associated with the change in SMI during follow-up (β − 0.1 (95% CI − 0.3 to − 0.02) kg/m2; p = 0.02), but not with a change in GS (β − 0.9 (95% CI − 1.9 to 0.04) kg) or TUG (β − 0.1 (95% CI − 0.7 to 0.5) s). Insulin therapy was positively associated with change in SMI (β 0.6 (95% CI 0.3–0.9) kg/m2; p = 0.001), but not in GS (β − 1.6 (95% CI − 4.1 to 0.8) kg) or TUG (β 1.6 (95% CI − 0.2–3.4) s) in comparison with treatment with oral anti-diabetic medication alone. Conclusions: Participants with T2D showed an accelerated decline in muscle mass compared to non-diabetic participants. Insulin therapy was associated with preserved muscle mass, but not muscle function parameters, indicating a discrepancy between muscle mass and function in this high-risk population. |
Databáze: | OpenAIRE |
Externí odkaz: |